Dr Deborah Rathjen

Chief Executive Officer & Managing Director

Dr Rathjen is a highly experienced and respected leader in the biotechnology and pharmaceutical industries within Australia and internationally, and has achieved in excess of $800 million in deals including partnerships with Merck & Co., J&J, Abbott (AbbVie), Celgene, Nycomed (Takeda) and Merck KGaA. An immunologist by training, Dr Rathjen has extensive R&D experience in the areas of infection and immunity, inflammation, oncology and neuroscience, covering multiple treatment modalities.

As well as heading up Carina Biotech, Dr Rathjen is currently a member of the, Microscopy Australia Board, Doherty Clinical Trials Board (Chair) and the Australian National Fabrication Facility (ANFF) Board.

Dr Deborah Rathjen Headshot